A Multiple Center, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients with Refractory Malignancies.
Phase of Trial: Phase I/II
Latest Information Update: 24 Jan 2014
At a glance
- Drugs IRX 4204 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 07 Oct 2011 Io Therapeutics reports that it has completed a phase I/II trial of IRX 4204 in patients with solid tumours.
- 06 Oct 2011 Status changed from discontinued to completed.
- 21 Oct 2010 Actual end date changed from Feb 2010 to Jun 2010 as reported by ClinicalTrials.gov.